New drug discovery strategies for the treatment of benznidazole-resistance in Trypanosoma cruzi, the causative agent of Chagas disease

References

• World Health Organization [Internet]. [cited 2022 Oct 24] Available from: https://www.who.int/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis)
   Google Scholar
• Hotez PJ, Picado A. The rise of neglected tropical diseases in the “new Texas. PLOS Negl Trop Dis. 2018;12(1):e0005581. doi: 10.1371/journal.pntd.0005581
   PubMed Web of Science ®Google Scholar
• Castillo-Riquelme M. Chagas disease in non-endemic countries. Lancet Glob Health. 2017;5(4):e379–e380. doi: 10.1016/S2214-109X(17)30090-6
   PubMed Web of Science ®Google Scholar
• Imai K, Misawa K, Osa M, et al. Chagas disease: a report of 17 suspected cases in Japan, 2012–2017. Trop Med Health. 2019;47(1):38. doi: 10.1186/s41182-019-0168-3
   PubMedGoogle Scholar
• Pérez-Molina JA, Molina I. Chagas disease. Lancet. 2018;391(10115):82–94. doi: 10.1016/S0140-6736(17)31612-4
   PubMed Web of Science ®Google Scholar
• Epstein D, Nusser N, Oliel S. PAHO Pan American Health Organization [Internet 70% of people with Chagas don’t know they’re infected. 2021 [cited 2022 Oct 15]. Available from: https://www.paho.org/en/news/13-4-2021-70-people-chagas-dont-know-theyre-infected
   Google Scholar
• Irish A, Whitman JD, Clark EH, et al. Updated estimates and mapping for prevalence of Chagas disease among adults, United States. Emerg Infect Dis. 2022;28(7):1313–1320. doi: 10.3201/eid2807.212221
   PubMed Web of Science ®Google Scholar
• Hasslocher-Moreno AM. Laboratory-acquired acute Chagas disease: a case report. J Clin Images Med Case Rep. 2022;3(5):3. doi: 10.52768/2766-7820/1833
   Google Scholar
• Ayres J, Marcus R, Standley CJ. The importance of screening for Chagas disease against the backdrop of changing epidemiology in the USA. Curr Trop Med Rep. 2022;9(4):185–193. doi: 10.1007/s40475-022-00264-7
   PubMedGoogle Scholar
• Sales Junior PA, Molina I, Fonseca Murta SM, et al. Experimental and clinical treatment of Chagas disease: a review. Am J Trop Med Hyg. 2017;97(5):1289–1303. doi: 10.4269/ajtmh.16-0761
   PubMed Web of Science ®Google Scholar
• Hall BS, Wilkinson SR. Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation. Antimicrob Agents Chemother. 2012;56(1):115–123. doi: 10.1128/AAC.05135-11
   PubMed Web of Science ®Google Scholar
• Trochine A, Creek DJ, Faral-Tello P, et al. Benznidazole biotransformation and multiple targets in Trypanosoma cruzi revealed by metabolomics. PLOS Negl Trop Dis. 2014;8(5):e2844. doi: 10.1371/journal.pntd.0002844
   PubMed Web of Science ®Google Scholar
• Rajão MA, Furtado C, Alves CL, et al. Unveiling Benznidazole’s mechanism of action through overexpression of DNA repair proteins in Trypanosoma cruzi. Environ Mol Mutagen. 2014;55(4):309–321. doi: 10.1002/em.21839
   PubMed Web of Science ®Google Scholar
• Trochine A, Alvarez G, Corre S, et al. Trypanosoma cruzi chemical proteomics using immobilized benznidazole. Exp Parasitol. 2014;140:33–38. doi: 10.1016/j.exppara.2014.03.013
   PubMed Web of Science ®Google Scholar
• Wilkinson SR, Taylor MC, Horn D, et al. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci, USA. 2008;105(13):5022–5027. doi: 10.1073/pnas.0711014105
   PubMed Web of Science ®Google Scholar
• Aldasoro E, Posada E, Requena-Méndez A, et al. What to expect and when: benznidazole toxicity in chronic Chagas’ disease treatment. J Antimicrob Chemother. 2018;73(4):1060–1067. doi: 10.1093/jac/dkx516
   PubMed Web of Science ®Google Scholar
• Vela A, Coral-Almeida M, Sereno D, et al. In vitro susceptibility of Trypanosoma cruzi discrete typing units (DTUs) to benznidazole: a systematic review and meta-analysis. PLOS Negl Trop Dis. 2021;15(3):e0009269. doi: 10.1371/journal.pntd.0009269
   PubMed Web of Science ®Google Scholar
• Zingales B, Andrade SG, Briones MRS, et al. A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. Mem Inst Oswaldo Cruz. 2009;104(7):1051–1054. doi: 10.1590/S0074-02762009000700021
   PubMed Web of Science ®Google Scholar
• Lima L, Espinosa-Álvarez O, Ortiz PA, et al. Genetic diversity of Trypanosoma cruzi in bats, and multilocus phylogenetic and phylogeographical analyses supporting Tcbat as an independent DTU (discrete typing unit). Acta Trop. 2015;151:166–177. doi: 10.1016/j.actatropica.2015.07.015
   PubMed Web of Science ®Google Scholar
• Zingales B, Miles MA, Moraes CB, et al. Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity. Mem Inst Oswaldo Cruz. 2014;109(6):828–833. doi: 10.1590/0074-0276140156
   PubMed Web of Science ®Google Scholar
• García-Huertas P, Mejía-Jaramillo AM, Machado CR, et al. Prostaglandin F2α synthase in Trypanosoma cruzi plays critical roles in oxidative stress and susceptibility to benznidazole. R Soc Open Sci. 2017;4(9):170773. doi: 10.1098/rsos.170773
   PubMed Web of Science ®Google Scholar
• Lima DA, Gonçalves LO, Reis-Cunha JL, et al. Transcriptomic analysis of benznidazole-resistant and susceptible Trypanosoma cruzi populations. Parasites Vectors. 2023;16(1):167. doi: 10.1186/s13071-023-05775-4
   PubMed Web of Science ®Google Scholar
• Petravicius PO, Costa-Martins AG, Silva MN, et al. Mapping benznidazole resistance in trypanosomatids and exploring evolutionary histories of nitroreductases and ABCG transporter protein sequences. Acta Trop. 2019;200:105161. doi: 10.1016/j.actatropica.2019.105161
   PubMed Web of Science ®Google Scholar
• Mejía-Jaramillo AM, Fernández GJ, Palacio L, et al. Gene expression study using real-time PCR identifies an NTR gene as a major marker of resistance to benznidazole in Trypanosoma cruzi. Parasites Vectors. 2011;4(1):169. doi: 10.1186/1756-3305-4-169
   PubMedGoogle Scholar
• Murta SMF, Krieger MA, Montenegro LR, et al. Deletion of copies of the gene encoding old yellow enzyme (TcOYE), a NAD(P)H flavin oxidoreductase, associates with in vitro-induced benznidazole resistance in Trypanosoma cruzi. Mol Biochem Parasitol. 2006;146(2):151–162. doi: 10.1016/j.molbiopara.2005.12.001
   PubMed Web of Science ®Google Scholar
• Díaz-Viraqué F, Chiribao ML, Trochine A, et al. Old yellow enzyme from Trypanosoma cruzi exhibits in vivo prostaglandin F2α synthase activity and has a key role in parasite infection and drug susceptibility. Front Immunol. 2018;9. doi: 10.3389/fimmu.2018.00456
   PubMed Web of Science ®Google Scholar
• García-Huertas P, Cardona-Castro N. Advances in the treatment of Chagas disease: promising new drugs, plants and targets. Biomed Pharmacother. 2021;142:112020. doi: 10.1016/j.biopha.2021.112020
   PubMed Web of Science ®Google Scholar
• Williams RE, Bruce NC. ‘New uses for an Old Enzyme’ – the Old Yellow Enzyme family of flavoenzymes. Microbiology. 2002;148(6):1607–1614. doi: 10.1099/00221287-148-6-1607
   PubMedGoogle Scholar
• Kubata BK, Kabututu Z, Nozaki T, et al. A key role for old yellow enzyme in the metabolism of drugs by Trypanosoma cruzi. J Exp Med. 2002;196(9):1241–1252. doi: 10.1084/jem.20020885
   PubMed Web of Science ®Google Scholar
• Santi AMM, Ribeiro JM, Reis-Cunha JL, et al. Disruption of multiple copies of the prostaglandin F2alpha synthase gene affects oxidative stress response and infectivity in Trypanosoma cruzi. PLOS Negl Trop Dis. 2022;16(10):e0010845. doi: 10.1371/journal.pntd.0010845
   PubMed Web of Science ®Google Scholar
• Santi AMM, Murta SMF. Antioxidant defence system as a rational target for Chagas disease and leishmaniasis chemotherapy. Mem Inst Oswaldo Cruz. 2022;117:117. doi: 10.1590/0074-02760210401
   Web of Science ®Google Scholar
• Zingales B, Araujo RGA, Moreno M, et al. A novel ABCG-like transporter of Trypanosoma cruzi is involved in natural resistance to benznidazole. Mem Inst Oswaldo Cruz. 2015;110(3):433–444. doi: 10.1590/0074-02760140407
   PubMed Web of Science ®Google Scholar
• Giorgi ME, Lederkremer RD. The glycan structure of T. cruzi mucins depends on the Host. Insights on the chameleonic galactose. Molecules. 2020;25(17):3913. doi: 10.3390/molecules25173913
   PubMed Web of Science ®Google Scholar
• Reis-Cunha JL, Valdivia HO, Bartholomeu DC. Gene and chromosomal copy number variations as an adaptive mechanism towards a parasitic lifestyle in Trypanosomatids. Curr Genomics. 2018;19(2). doi: 10.2174/1389202918666170911161311
   PubMed Web of Science ®Google Scholar
• Reis-Cunha JL, Rodrigues-Luiz GF, Valdivia HO, et al. Chromosomal copy number variation reveals differential levels of genomic plasticity in distinct Trypanosoma cruzi strains. BMC Genomics. 2015;16(1):499. doi: 10.1186/s12864-015-1680-4
   PubMedGoogle Scholar
• Bartholomeu DC, Cerqueira GC, Leão ACA, et al. Genomic organization and expression profile of the mucin-associated surface protein (masp) family of the human pathogen Trypanosoma cruzi. Nucleic Acids Res. 2009;37(10):3407–3417. doi: 10.1093/nar/gkp172
   PubMed Web of Science ®Google Scholar
• Oliveira C, Holetz FB, Alves LR, et al. Modulation of virulence factors during Trypanosoma cruzi differentiation. Pathogens. 2022;12(1):32. doi: 10.3390/pathogens12010032
   PubMed Web of Science ®Google Scholar
• Moreira DDS, Duarte AP, Pais FSM, et al. Overexpression of eukaryotic initiation factor 5A (eIF5A) affects susceptibility to benznidazole in Trypanosoma cruzi populations. Mem Inst Oswaldo Cruz. 2018;113(9):113. doi: 10.1590/0074-02760180162
   Web of Science ®Google Scholar
• Gupta I, Aggarwal S, Singh K, et al. Ubiquitin proteasome pathway proteins as potential drug targets in parasite Trypanosoma cruzi. Sci Rep. 2018;8(1):8399. doi: 10.1038/s41598-018-26532-z
   PubMedGoogle Scholar
• Perdomo VG, Rigalli JP, Luquita MG, et al. Up-regulation of ATP-binding cassette transporters in the THP-1 human macrophage cell line by the antichagasic benznidazole. Mem Inst Oswaldo Cruz. 2016;111(11):707–711. doi: 10.1590/0074-02760160080
   PubMed Web of Science ®Google Scholar
• Téllez J, Romero I, Romanha AJ, et al. Drug transporter and oxidative stress gene expression in human macrophages infected with benznidazole-sensitive and naturally benznidazole-resistant Trypanosoma cruzi parasites treated with benznidazole. Parasites Vectors. 2019;12(1):262. doi: 10.1186/s13071-019-3485-9
   PubMedGoogle Scholar
• Nogueira FB, Rodrigues JFA, Correa MMS, et al. The level of ascorbate peroxidase is enhanced in benznidazole-resistant populations of Trypanosoma cruzi and its expression is modulated by stress generated by hydrogen peroxide. Mem Inst Oswaldo Cruz. 2012;107(4):494–502. doi: 10.1590/S0074-02762012000400009
   PubMed Web of Science ®Google Scholar
• Libisch MG, Rego N, Robello C. Transcriptional studies on Trypanosoma cruzi – Host cell interactions: a complex puzzle of variables. Front Cell Infect Microbiol. 2021;11:11. doi: 10.3389/fcimb.2021.692134
   Web of Science ®Google Scholar
• Teston APM, Fernandes NDS, Abegg CP, et al. Therapeutic effects of benznidazole in Swiss mice that are orally inoculated with Trypanosoma cruzi IV strains from the western Brazilian Amazon. Exp Parasitol. 2021;228:108136. doi: 10.1016/j.exppara.2021.108136
   PubMed Web of Science ®Google Scholar
• Revollo S, Oury B, Vela A, et al. In vitro benznidazole and Nifurtimox Susceptibility Profile of Trypanosoma cruzi strains belonging to discrete typing units TcI, TcII, and TcV. Pathogens. 2019;8(4):197. doi: 10.3390/pathogens8040197
   PubMed Web of Science ®Google Scholar
• Fonseca KDS, Perin L, de Paiva NCN, et al. Benznidazole treatment: time- and dose-dependence varies with the Trypanosoma cruzi strain. Pathogens. 2021;10(6):729. doi: 10.3390/pathogens10060729
   PubMed Web of Science ®Google Scholar
• Kratz JM, Gonçalves KR, Romera LM, et al. The translational challenge in Chagas disease drug development. Mem Inst Oswaldo Cruz. 2022;117:117. doi: 10.1590/0074-02760200501
   Web of Science ®Google Scholar
• Buckner FS, Verlinde CL, La Flamme AC, et al. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase. Antimicrob Agents Chemother. 1996;40(11):2592–2597. doi: 10.1128/AAC.40.11.2592
   PubMed Web of Science ®Google Scholar
• Miranda CG, Solana ME, Curto MDLA, et al. A flow cytometer-based method to simultaneously assess activity and selectivity of compounds against the intracellular forms of Trypanosoma cruzi. Acta Trop. 2015;152:8–16. doi: 10.1016/j.actatropica.2015.08.004
   PubMed Web of Science ®Google Scholar
• Canavaci AMC, Bustamante JM, Padilla AM, et al. In vitro and in vivo high-throughput assays for the testing of Anti-Trypanosoma cruzi compounds. PLOS Negl Trop Dis. 2010;4(7):e740. doi: 10.1371/journal.pntd.0000740
   PubMed Web of Science ®Google Scholar
• Hyland KV, Asfaw SH, Olson CL, et al. Bioluminescent imaging of Trypanosoma cruzi infection. Int J Parasitol. 2008;38(12):1391–1400. doi: 10.1016/j.ijpara.2008.04.002
   PubMed Web of Science ®Google Scholar
• Bettiol E, Samanovic M, Murkin AS, et al. Identification of three classes of heteroaromatic compounds with activity against intracellular Trypanosoma cruzi by chemical library screening. PLOS Negl Trop Dis. 2009;3(2):e384. doi: 10.1371/journal.pntd.0000384
   PubMed Web of Science ®Google Scholar
• Engel JC, Ang KKH, Chen S, et al. Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas’ disease. Antimicrob Agents Chemother. 2010;54:3326–3334. doi: 10.1128/AAC.01777-09
   PubMed Web of Science ®Google Scholar
• Moon S, Siqueira-Neto JL, Moraes CB, et al. An image-based algorithm for precise and accurate high throughput assessment of drug activity against the human parasite Trypanosoma cruzi. PLOS ONE. 2014;9(2):e87188. doi: 10.1371/journal.pone.0087188
   PubMed Web of Science ®Google Scholar
• Alonso-Padilla J, Cotillo I, Presa JL, et al. Automated high-content assay for compounds selectively toxic to Trypanosoma cruzi in a myoblastic cell line. PLOS Negl Trop Dis. 2015;9(1):e0003493. doi: 10.1371/journal.pntd.0003493
   PubMed Web of Science ®Google Scholar
• De Rycker M, Thomas J, Riley J, et al. Identification of trypanocidal activity for known clinical compounds using a new Trypanosoma cruzi hit-discovery screening cascade. PLOS Negl Trop Dis. 2016;10(4):e0004584. doi: 10.1371/journal.pntd.0004584
   PubMed Web of Science ®Google Scholar
• Svensen N, Wyllie S, Gray DW, et al. Live-imaging rate-of-kill compound profiling for Chagas disease drug discovery with a new automated high-content assay. PLOS Negl Trop Dis. 2021;15(10):e0009870. doi: 10.1371/journal.pntd.0009870
   PubMed Web of Science ®Google Scholar
• De Rycker M, Wyllie S, Horn D, et al. Anti-trypanosomatid drug discovery: progress and challenges. Nat Rev Microbiol. 2023;21(1):35–50. doi: 10.1038/s41579-022-00777-y
   PubMed Web of Science ®Google Scholar
• Romanha AJ, Castro SD, Soeiro MDN, et al. In vitro and in vivo experimental models for drug screening and development for Chagas disease. Mem Inst Oswaldo Cruz. 2010;105(2):233–238. doi: 10.1590/S0074-02762010000200022
   PubMed Web of Science ®Google Scholar
• Chatelain E. Chagas disease drug discovery: toward a new era. Slas Discovery. 2015;20(1):22–35. doi: 10.1177/1087057114550585
   Google Scholar
• Sánchez-Valdéz FJ, Padilla A, Wang W, et al. Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure. Elife. 2018;7. doi: 10.7554/eLife.34039
   PubMed Web of Science ®Google Scholar
• Soeiro MDN. Perspectives for a new drug candidate for Chagas disease therapy. Mem Inst Oswaldo Cruz. 2022;117:117. doi: 10.1590/0074-02760220004
   Web of Science ®Google Scholar
• Gabaldón-Figueira JC, Martinez-Peinado N, Escabia E, et al. State-of-the-art in the drug discovery pathway for Chagas disease: a framework for drug development and target validation. Res Rep Trop Med. 2023;14:1–19. doi: 10.2147/RRTM.S415273
   PubMed Web of Science ®Google Scholar
• Fiuza LDA, Batista DGJ, Girão RD, et al. Phenotypic evaluation of nucleoside analogues against Trypanosoma cruzi infection: in vitro and in vivo approaches. Molecules. 2022;27(22):8087. doi: 10.3390/molecules27228087
   PubMed Web of Science ®Google Scholar
• Orlando LMR, Lechuga GC, da Silva Lara L, et al. Structural optimization and biological activity of pyrazole derivatives: virtual computational analysis, recovery assay and 3D culture model as potential predictive tools of effectiveness against Trypanosoma cruzi. Molecules. 2021;26(21):6742. doi: 10.3390/molecules26216742
   PubMed Web of Science ®Google Scholar
• Chatelain E, Scandale I. Animal models of Chagas disease and their translational value to drug development. Expert Opin Drug Discov. 2020;15(12):1381–1402. doi: 10.1080/17460441.2020.1806233
   PubMed Web of Science ®Google Scholar
• Francisco AF, Lewis MD, Jayawardhana S, et al. Limited ability of posaconazole to cure both acute and chronic Trypanosoma cruzi infections revealed by highly sensitive in vivo imaging. Antimicrob Agents Chemother. 2015;59(8):4653–4661. doi: 10.1128/AAC.00520-15
   PubMed Web of Science ®Google Scholar
• Andriani G, Chessler A-D, Courtemanche G, et al. Activity in vivo of Anti-Trypanosoma cruzi compounds selected from a high throughput screening. PLOS Negl Trop Dis. 2011;5:e1298. doi: 10.1371/journal.pntd.0001298
   PubMed Web of Science ®Google Scholar
• de Lana M, Giunchetti RC. Dogs as a Model for chemotherapy of Chagas disease and leishmaniasis. Curr Pharm Des. 2021;27(14):1741–1756. doi: 10.2174/1381612826666201228142703
   PubMed Web of Science ®Google Scholar
• Palmeiro-Roldán R, Fonseca-Berzal C, Gómez-Barrio A, et al. Development of novel benznidazole formulations: physicochemical characterization and in vivo evaluation on parasitemia reduction in Chagas disease. Int J Pharm. 2014;472(1–2):110–117. doi: 10.1016/j.ijpharm.2014.06.015
   PubMedGoogle Scholar
• Mazzeti AL, Oliveira LT, Gonçalves KR, et al. Benznidazole self-emulsifying delivery system: a novel alternative dosage form for Chagas disease treatment. Eur J Pharm Sci. 2020;145:105234. doi: 10.1016/j.ejps.2020.105234
   PubMed Web of Science ®Google Scholar
• García MC, Eberhardt N, Sanmarco LM, et al. Improved efficacy and safety of low doses of benznidazole-loaded multiparticulate delivery systems in experimental Chagas disease therapy. Eur J Pharm Sci. 2021;164:105912. doi: 10.1016/j.ejps.2021.105912
   PubMed Web of Science ®Google Scholar
• Arrua EC, Hartwig O, Loretz B, et al. Formulation of benznidazole-lipid nanocapsules: drug release, permeability, biocompatibility, and stability studies. Int J Pharm. 2023;642:123120. doi: 10.1016/j.ijpharm.2023.123120
   PubMedGoogle Scholar
• Silva FD, Marques MDF, Yoshida MI, et al. Encapsulation of benznidazole in nanostructured lipid carriers and increased trypanocidal activity in a resistant Trypanosoma cruzi strain. Braz J Pharm Sci. 2023;59:59. doi: 10.1590/s2175-97902023e22111
   Web of Science ®Google Scholar
• Bustamante JM, Sanchez-Valdez F, Padilla AM, et al. A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease. Sci Transl Med. 2020;12(567):12. doi: 10.1126/scitranslmed.abb7656
   Web of Science ®Google Scholar
• Bustamante JM, White BE, Wilkerson GK, et al. Frequency variation and dose modification of benznidazole administration for the treatment of Trypanosoma cruzi infection in mice, dogs, and nonhuman primates. Antimicrob Agents Chemother. 2023;67(5):67. doi: 10.1128/aac.00132-23
   Web of Science ®Google Scholar
• Molina-Morant D, Fernández ML, Bosch-Nicolau P, et al. Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized phase II superiority clinical trial. Trials. 2020;21(1):328. doi: 10.1186/s13063-020-4226-2
   PubMed Web of Science ®Google Scholar
• Bosch-Nicolau P, Fernández ML, Sulleiro E, et al. Efficacy of three benznidazole dosing strategies for adults living with chronic Chagas disease (MULTIBENZ): an international, randomised, double-blind, phase 2b trial. Lancet Infect Dis. 2024;24(4):386–394. doi: 10.1016/S1473-3099(23)00629-1
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Shorter benznidazole regimens compared to the standard regimen for Chagas disease (NuestroBen). Bethesda (MD): National Library of Medicine (US). Identifier NCT04897516; [cited 2024 Apr 4]. Available from: https://clinicaltrials.gov/study/NCT04897516?cond=Chagas%20Disease&intr=Benznidazole&page=1&rank=6&limit=10
   Google Scholar
• Leite DI, Fontes FDV, Bastos MM, et al. New 1,2,3‐triazole‐based analogues of benznidazole for use against Trypanosoma cruzi infection: in vitro and in vivo evaluations. Chem Biol Drug Des. 2018;92(3):1670–1682. doi: 10.1111/cbdd.13333
   PubMed Web of Science ®Google Scholar
• Assunção ELF, Carvalho DB, Das Neves AR, et al. Synthesis and antitrypanosomal activity of 1,4‐Disubstituted triazole compounds based on a 2‐Nitroimidazole scaffold: a Structure‐activity relationship study. ChemMedchem. 2020;15(21):2019–2028. doi: 10.1002/cmdc.202000460
   PubMed Web of Science ®Google Scholar
• Do Vale Chaves E, Mello F, Castro Salomão Quaresma BM, et al. Novel nitroimidazole derivatives evaluated for their trypanocidal, cytotoxic, and genotoxic activities. Eur J Med Chem. 2020;186:111887. doi: 10.1016/j.ejmech.2019.111887
   PubMed Web of Science ®Google Scholar
• Carvalho DB, Costa PAN, Portapilla GB, et al. Design, synthesis and antitrypanosomatid activity of 2-nitroimidazole-3,5-disubstituted isoxazole compounds based on benznidazole. Eur J Med Chem. 2023;260:115451. doi: 10.1016/j.ejmech.2023.115451
   PubMed Web of Science ®Google Scholar
• Beltran-Hortelano I, Atherton RL, Rubio-Hernández M, et al. Design and synthesis of mannich base-type derivatives containing imidazole and benzimidazole as lead compounds for drug discovery in Chagas disease. Eur J Med Chem. 2021;223:113646. doi: 10.1016/j.ejmech.2021.113646
   PubMed Web of Science ®Google Scholar
• Fersing C, Boudot C, Castera-Ducros C, et al. 8-alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T. b. brucei and cruzi. Eur J Med Chem. 2020;202:112558. doi: 10.1016/j.ejmech.2020.112558
   PubMed Web of Science ®Google Scholar
• Thompson AM, O’Connor PD, Marshall AJ, et al. 7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1- b]1,3]oxazines: novel antitubercular agents lead to a new preclinical Candidate for visceral leishmaniasis. J Med Chem. 2017;60(10):4212–4233. doi: 10.1021/acs.jmedchem.7b00034
   PubMed Web of Science ®Google Scholar
• Thompson AM, O’Connor PD, Blaser A, et al. Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1- b]1,3]oxazoles for neglected tropical diseases: structure–activity studies on a preclinical candidate for visceral leishmaniasis. J Med Chem. 2016;59(6):2530–2550. doi: 10.1021/acs.jmedchem.5b01699
   PubMed Web of Science ®Google Scholar
• Mathias F, Cohen A, Kabri Y, et al. Synthesis and in vitro evaluation of new 5-substituted 6-nitroimidazooxazoles as antikinetoplastid agents. Eur J Med Chem. 2020;191:112146. doi: 10.1016/j.ejmech.2020.112146
   PubMed Web of Science ®Google Scholar
• Ang CW, Tan L, Sykes ML, et al. Antitubercular and antiparasitic 2-nitroimidazopyrazinones with improved potency and solubility. J Med Chem. 2020;63(24):15726–15751. doi: 10.1021/acs.jmedchem.0c01372
   PubMed Web of Science ®Google Scholar
• Ang CW, Lee BM, Jackson CJ, et al. Nitroimidazopyrazinones with oral activity against tuberculosis and Chagas disease in mouse models of infection. J Med Chem. 2022;65(19):13125–13142. doi: 10.1021/acs.jmedchem.2c00972
   PubMed Web of Science ®Google Scholar
• Laureano de Souza M, Lapierre TJWJD, Marques GVL, et al. Molecular targets for Chagas disease: validation, challenges and lead compounds for widely exploited targets. Expert Opin Ther Targets. 2023;27:911–925. doi: 10.1080/14728222.2023.2264512
   PubMed Web of Science ®Google Scholar
• Müller Kratz J, Garcia Bournissen F, Forsyth CJ, et al. Clinical and pharmacological profile of benznidazole for treatment of Chagas disease. Expert Rev Clin Pharmacol. 2018;11(10):943–957. doi: 10.1080/17512433.2018.1509704
   PubMed Web of Science ®Google Scholar
• Araujo MSS, Martins-Filho OA, Pereira MES, et al. A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas’ disease. J Antimicrob Chemother. 2000;45(6):819–824. doi: 10.1093/jac/45.6.819
   PubMed Web of Science ®Google Scholar
• Diniz LDF, Urbina JA, de Andrade IM, et al. Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments. PLOS Negl Trop Dis. 2013;7(8):e2367. doi: 10.1371/journal.pntd.0002367
   PubMed Web of Science ®Google Scholar
• Echeverría LE, González CI, Hernandez JCM, et al. Efficacy of the Benznidazole+Posaconazole combination therapy in parasitemia reduction: an experimental murine model of acute chagas. Rev Soc Bras Med Trop. 2020;53:53. doi: 10.1590/0037-8682-0477-2019
   Web of Science ®Google Scholar
• de F DL, Mazzeti AL, Caldas IS, et al. Outcome of E1224-benznidazole combination treatment for infection with a multidrug-resistant Trypanosoma cruzi strain in mice. Antimicrob Agents Chemother. 2018;62(6):62. doi: 10.1128/AAC.00401-18
   Web of Science ®Google Scholar
• Cunha ELA, Torchelsen FDS, Cunha LM, et al. Benznidazole, itraconazole and their combination in the treatment of acute experimental Chagas disease in dogs. MethodsX. 2019;6:2544–2552. doi: 10.1016/j.mex.2019.10.007
   PubMed Web of Science ®Google Scholar
• Assíria Fontes Martins T, de Figueiredo Diniz L, Mazzeti AL, et al. Benznidazole/Itraconazole combination treatment enhances anti-Trypanosoma cruzi activity in experimental Chagas disease. PLOS ONE. 2015;10(6):e0128707. doi: 10.1371/journal.pone.0128707
   PubMed Web of Science ®Google Scholar
• Gulin JEN, Eagleson MA, López-Muñoz RA, et al. In vitro and in vivo activity of voriconazole and benznidazole combination on Trypanosoma cruzi infection models. Acta Trop. 2020;211:105606. doi: 10.1016/j.actatropica.2020.105606
   PubMed Web of Science ®Google Scholar
• Batista DDG, Batista MM, Oliveira GD, et al. Combined treatment of heterocyclic analogues and benznidazole upon Trypanosoma cruzi in vivo. PLOS ONE. 2011;6(7):e22155. doi: 10.1371/journal.pone.0022155
   PubMed Web of Science ®Google Scholar
• Pereira RS, Malvezi AD, Lovo-Martins MI, et al. Combination therapy using benznidazole and aspirin during the acute phase of experimental Chagas disease prevents cardiovascular dysfunction and decreases typical cardiac lesions in the chronic phase. Antimicrob Agents Chemother. 2020;64(7):64. doi: 10.1128/AAC.00069-20
   Web of Science ®Google Scholar
• Bustamante JM, Craft JM, Crowe BD, et al. New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice. J Infect Dis. 2014;209(1):150–162. doi: 10.1093/infdis/jit420
   PubMed Web of Science ®Google Scholar
• Almeida-Silva J, Menezes DS, Fernandes JMP, et al. The repositioned drugs disulfiram/diethyldithiocarbamate combined to benznidazole: searching for Chagas disease selective therapy, preventing toxicity and drug resistance. Front Cell Infect Microbiol. 2022;12:12. doi: 10.3389/fcimb.2022.926699
   Web of Science ®Google Scholar
• García MC, Ponce NE, Sanmarco LM, et al. Clomipramine and Benznidazole Act Synergistically and ameliorate the outcome of experimental Chagas disease. Antimicrob Agents Chemother. 2016;60(6):3700–3708. doi: 10.1128/AAC.00404-16
   PubMed Web of Science ®Google Scholar
• Shrestha D, Penitente AR, Horta AL, et al. Enalapril in combination with benznidazole reduces cardiac inflammation and creatine kinases in mice chronically infected with Trypanosoma cruzi. Am J Trop Med Hyg. 2015;93(5):976–982. doi: 10.4269/ajtmh.15-0237
   PubMed Web of Science ®Google Scholar
• Pandey RP, Nascimento MS, Franco CH, et al. Drug repurposing in Chagas disease: chloroquine potentiates benznidazole activity against Trypanosoma cruzi in vitro and in vivo. Antimicrob Agents Chemother. 2022;66(11):e0028422. doi: 10.1128/aac.00284-22
   PubMed Web of Science ®Google Scholar
• Sbaraglini ML, Bellera CL, Fraccaroli L, et al. Novel cruzipain inhibitors for the chemotherapy of chronic Chagas disease. Int J Antimicrob Agents. 2016;48(1):91–95. doi: 10.1016/j.ijantimicag.2016.02.018
   PubMed Web of Science ®Google Scholar
• Sbaraglini ML, Bellera CL, Quarroz Braghini J, et al. Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease. Eur J Med Chem. 2019;184:111778. doi: 10.1016/j.ejmech.2019.111778
   PubMed Web of Science ®Google Scholar
• Morillo CA, Waskin H, Sosa-Estani S, et al. Benznidazole and posaconazole in eliminating parasites in asymptomatic T. Cruzi Carriers. J Am Coll Cardiol. 2017;69(8):939–947. doi: 10.1016/j.jacc.2016.12.023
   PubMed Web of Science ®Google Scholar
• Torrico F, Gascón J, Barreira F, et al. New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial. Lancet Infect Dis. 2021;21(8):1129–1140. doi: 10.1016/S1473-3099(20)30844-6
   PubMed Web of Science ®Google Scholar
• Luo Y, Zhao X, Zhou J, et al. A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information. Nat Commun. 2017;8(1):573. doi: 10.1038/s41467-017-00680-8
   PubMedGoogle Scholar
• Varadi M, Anyango S, Deshpande M, et al. AlphaFold protein structure database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 2022;50(D1):D439–D444. doi: 10.1093/nar/gkab1061
   PubMed Web of Science ®Google Scholar
• Ding Y, Tang J, Guo F. The computational models of drug-target interaction prediction. Protein Pept Lett. 2020;27(5):348–358. doi: 10.2174/0929866526666190410124110
   PubMed Web of Science ®Google Scholar
• Ezzat A, Wu M, Li X, et al. Computational prediction of drug-target interactions via ensemble learning. Methods Mol Biol. 2019;1903:239–254.
   PubMedGoogle Scholar
• Zong N, Li N, Wen A, et al. BETA: a comprehensive benchmark for computational drug–target prediction. Brief Bioinform. 2022;23(4):23. doi: 10.1093/bib/bbac199
   Web of Science ®Google Scholar
• Wang X, Pan C, Gong J, et al. Enhancing the enrichment of pharmacophore-based target prediction for the polypharmacological profiles of drugs. J Chem Inf Model. 2016;56(6):1175–1183. doi: 10.1021/acs.jcim.5b00690
   PubMed Web of Science ®Google Scholar
• Santos CC, Lionel JR, Peres RB, et al. In vitro ,in Silico , and in vivo analyses of novel aromatic amidines against Trypanosoma cruzi. Antimicrob Agents Chemother. 2018;62(2):62. doi: 10.1128/AAC.02205-17
   Web of Science ®Google Scholar
• Cronin MTD, Enoch SJ, Mellor CL, et al. In silico prediction of organ level toxicity: linking chemistry to adverse effects. Toxicol Res. 2017;33(3):173–182. doi: 10.5487/TR.2017.33.3.173
   PubMedGoogle Scholar
• Ferreira LLG, Andricopulo AD. ADMET modeling approaches in drug discovery. Drug Discov Today. 2019;24(5):1157–1165. doi: 10.1016/j.drudis.2019.03.015
   PubMed Web of Science ®Google Scholar
• Menozzi CAC, França RRF, Luccas PH, et al. Anti-Trypanosoma cruzi activity, mutagenicity, Hepatocytotoxicity and nitroreductase enzyme evaluation of 3-nitrotriazole, 2-nitroimidazole and triazole derivatives. Molecules. 2023;28(22):7461. doi: 10.3390/molecules28227461
   PubMed Web of Science ®Google Scholar